



an  **Almirall** company

## **News Release**

Aqua Pharmaceuticals, LLC  
Lisa Wilk, 610-644-7000

### **Aqua Pharmaceuticals, LLC Announces Launch of Cordran® Ointment (flurandrenolide ointment, USP) 0.05%**

West Chester, Pa. — June 30, 2014

West Chester-based Aqua Pharmaceuticals, an Almirall company, today announces the launch of Cordran® Ointment (flurandrenolide ointment, USP) 0.05%. Cordran® Ointment is a Class 4 topical corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

“Cordran® is a name well-known throughout the dermatology community,” said Ted White, Chief Operating Officer at Aqua. “For quite some time, physicians have relied on Cordran® Lotion and Cordran® Cream to help treat a variety of skin conditions. With the launch of Cordran® Ointment, physicians will have another tool in the bag to provide the best quality care for their patients.”

Cordran® Ointment is preservative-free and does not contain propylene glycol. Because of its ointment formulation, Cordran® Ointment may be particularly helpful for patients with very dry skin. It is supplied in 60 gram aluminum tubes.

### **Important Safety Information Regarding Cordran® Lotion, Cream and Ointment 0.05%**

- Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, Cushing’s syndrome, hyperglycemia, and glucosuria.
- Increased absorption may occur with the use of more potent steroids, use over large surface areas or with occlusive dressings, prolonged use, or use in pediatric patients.
- Patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression using urine free cortisol and ACTH stimulation tests.
- Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than do adults because of a larger skin surface area to body weight ratio.
- Local adverse reactions are reported infrequently with topical corticosteroids but may occur more frequently with the use of occlusive dressings.
- The most common adverse events with Cordran® were burning, itching, irritation, and dryness.
- The following adverse reactions have been identified during post-approval use of Cordran®: hypersensitivity, contact dermatitis, skin discoloration, skin striae and skin atrophy.

**About Aqua Pharmaceuticals**

Headquartered in West Chester, Pennsylvania, Aqua Pharmaceuticals, an Almirall company, is dedicated to helping patients achieve their goals of healthy skin and a positive self-image. The company has leading branded prescription drugs in four therapeutic categories that include acne, steroid-responsive dermatoses, actinic keratoses and seborrheic dermatitis. For more information, visit [www.aquapharm.com](http://www.aquapharm.com).

###